Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 2613 (LINC02613)
- Target
- LINC02613
- Molecular classification
- Long non-coding RNA (lncRNA), Other (non-protein coding RNA)
01
Overview
Long intergenic non-protein coding RNA 2613 (LINC02613) is a long non-coding RNA transcribed from the 2p22.1 region of the human genome. It is not translated into protein but regulates gene expression, notably through pathways influencing the cell cycle, DNA replication, and metabolic reprogramming. LINC02613 acts as a scaffold and epigenetic regulator, with emerging evidence linking its downregulation to poor prognosis in breast cancer and low expression seen in many tumor types. It modulates antitumor immunity, showing positive correlation with immune cell infiltration (CD8+ T cells, macrophages, dendritic cells, regulatory T cells). Its suppression appears to activate Wnt signaling (through increased Wnt2/Wnt3), promoting cell proliferation and glycolysis typical of cancer cells. As of now, LINC02613 is used mainly as a prognostic biomarker and is not a direct target for any approved or experimental drugs, nor is there evidence of safety concerns related to its modulation.
- Other names
- LINC02613Long intergenic non-protein coding RNA 2613
02
Mechanism of action
None currently established, as no drugs directly target LINC02613
03
Biological functions
Regulation of cell cycleDNA replicationGene expression control (epigenetics, scaffolding)Immune response activation and infiltrationScaffold formation and epigenetic controlGlycolysis and metabolic reprogramming
04
Disease associations
Cancer (namely breast cancer, with expression also downregulated across various other tumor types: bladder, ovarian, colon, liver, prostate, lung, melanoma, testicular germ cell, and several others)Other (Role in immune system distinction among cancer subtypes)
05
Safety considerations
None specifically reported, as it is not a therapeutic or drug targetBiological roles in cell cycle and immune response suggest that dysregulation may influence tumorigenesis and immunity, but therapeutic challenges are not described
06
Biomarkers
LINC02613 itself is being studied as a prognostic biomarker in breast cancer and potentially other tumor contextsDownregulation associated with poor overall survival and more advanced clinicopathological stage
Beyond the preview
Go deeper on Long intergenic non-protein coding RNA 2613 (LINC02613).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Long intergenic non-protein coding RNA 2613 (LINC02613).